Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer

February 2011 | 59 pages | ID: O97897E2316EN
The Assessment Group

Abstracts

Treatment decisions for advanced stages of renal cell cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

Primary research for the oncology prescribing data that you are missing, directly from high-prescribing US oncologists: what they prescribe, when, and why. Case highlights include:

Older patient with retroperitoneal adenopathy and small lung nodules

• Anemic patient with extremely high LDH levels
• Patient with multiple comorbidities including heart and lung disease
• Patient with one kidney and comorbidities

This report allows you to:

• Understand what occurs in the onologist’s office with actual patients
• Access the most up-to-date prescribing trends
• Gain actionable data for developing & improving market strategies
• Pinpoint needs of your target audience
• Design messages to advance brand performance
• Focus resources to maximize the effectiveness of your budget
• Understand where your competitor’s product fits

Contents

Executive Summary

CHAPTER 1: INTRODUCTION

Table 1. Treatment Options in Metastatic Breast Cancer

CHAPTER 2: RESPONDENT DEMOGRAPHICS

Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State’s Breast Cancer Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen

CHAPTER 3: TREATMENT OF A PATIENT WITH TRIPLE NEGATIVE METASTATIC BREAST CANCER

Figure 3.1Choice of chemotherapy regimen, triple negative metastatic breast cancer
Figure 3.2 Single chemotherapy choices, triple negative metastatic breast cancer
Figure 3.3 Combination chemotherapy choices, triple negative metastatic breast cancer
Figure 3.4 Factors influencing treatment of triple negative metastatic breast cancer
Figure 3.5 Confidence managing patient with triple negative metastatic breast cancer
Figure 3.6 Other agents appropriate to include in treatment of triple negative metastatic breast cancer
Figure 3.7 Treatment of progressive triple negative metastatic breast cancer
Figure 3.8 Single chemotherapy agent, progressive triple negative metastatic breast cancer
Figure 3.9 Combination chemotherapy, progressive triple negative metastatic breast cancer
Figure 3.10 Barriers to optimal treatment of progressive triple negative metastatic breast cancer
Figure 3.11 Changing therapy to manage neuropathy
Figure 3.12 Recommended treatment of progressive triple negative metastatic breast cancer with BRCA-1 mutation
Figure 3.13 Single agent chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation
Figure 3.14 Combination chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation

CHAPTER 4: TREATMENT OF PATIENT WITH TRIPLE POSITIVE METASTATIC BREAST CANCER

Figure 4.1 Next step for patient with triple positive metastatic breast cancer
Figure 4.2 Treatment of progressive disease, triple positive metastatic breast cancer
Figure 4.3 Single chemotherapy choices for progressive triple positive metastatic breast cancer
Figure 4.4 Combination chemotherapy, progressive triple positive metastatic breast cancer
Figure 4.5 Factors influencing treatment of progressive triple positive metastatic breast cancer
Figure 4.6 Treatment regimen for continued progression of triple positive metastatic breast cancer
Figure 4.7 Decisions regarding the use of lapatinib in progressive triple positive metastatic breast cancer
Figure 4.8 Management of progressive disease, triple positive metastatic breast cancer

CHAPTER 5: PATIENT WITH ER/PR POSITIVE HER2NEU NEGATIVE METASTATIC BREAST CANCER

Figure 5.1 Confidence managing patient with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.2 Other than analgesics, treatment of patient’s hip pain with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.3 Treatment with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.4 Factors influencing treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.5 Next systemic treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer

CHAPTER 6: PATIENT WITH METASTATIC BREAST CANCER WITH MULTIPLE COMORBIDITIES

Figure 6.1 Confidence managing patient with metastatic breast cancer with multiple comorbidities
Figure 6.2 Barriers to managing patient, metastatic breast cancer with multiple comorbidities
Figure 6.3 Treatment in addition to the aromatase inhibitor for patient’s metastatic breast cancer with multiple comorbidities
Figure 6.4 Next treatment regimen for progressive metastatic breast cancer with multiple comorbidities
Figure 6.5 Factors influencing treatment for progressive metastatic breast cancer with multiple comorbidities

CHAPTER 7: SUMMARY

Appendix A: Survey Instrument